Sigachi Industries Limited, a renowned name in the excipient segment of pharmaceutical industry, is excited to announce its strategic expansion into the API (Active Pharmaceutical Ingredient) business with the successful acquisition of majority stake (80%) of a state-of-the-art API manufacturing company, Trimax Bio Sciences, located in Raichur, Karnataka.

The acquisition marks a significant milestone in Sigachi's journey as it reinforces it’s commitment to providing cutting-edge solutions to the global pharmaceutical market. With this strategic move, Sigachi is poised to solidify its position as a leading player in the healthcare industry, catering to the growing demand for high-quality APIs.

The API unit, located in Raichur, Karnataka, 180kms from Hyderabad, is equipped with cutting-edge technology and is in compliance with the stringent international quality standards of USFDA, EMEA and WHO. Additionally, the API unit is approved by USFDA for advanced & critical intermediates. With a well-established track record of excellence in research, development, and manufacturing, the acquired API unit will synergize seamlessly with Sigachi's existing portfolio of excipients and will provide one stop solution for customer’s API & non-API needs.

Commenting on this strategic development, Mr. Amit Raj Sinha the MD & CEO of Sigachi Industries Limited, stated, "We are thrilled to venture into the API business, which presents vast opportunities to further strengthen our presence in the pharmaceutical industry. The acquisition of this well-equipped API unit aligns perfectly with our mission to deliver superior healthcare solutions globally. This expansion is a testament to our commitment to innovation and customer satisfaction."

The API market plays a crucial role in the pharmaceutical industry, providing the essential building blocks for various medications. With this acquisition, Sigachi is set to enhance its capabilities in developing and supplying a diverse range of APIs, catering to a wide spectrum of therapeutic areas, including cardiovascular, anti-diabetic, anti-infective, anti-viral, and central nervous system medications, among others with molecules like Pregabalin, Ritonavir, Metformin Hcl, Propafenone Hcl, Atorvastatin Ca Trihydrate, Nimorazole, Naftopidil, Meclizine Hcl & their intermediates.

Sigachi Industries Limited envisions becoming a key player in the API market by leveraging its strong R&D capabilities, cutting-edge manufacturing infrastructure, and unwavering focus on quality. With a strong expertise in excipient manufacturing for Oral Dosage Formulation built over last three decades, Sigachi's foray into API business opens up new doors for further collaboration with it’s customer operating in over 60 countries.